<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Janine</forename><surname>Kr€ Uger</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Cardiovascular Research/CCR</orgName>
								<orgName type="department" key="dep2">Institute of Laboratory Medicine</orgName>
								<orgName type="department" key="dep3">Clinical Chemistry and Pathobiochemistry</orgName>
								<orgName type="institution">Charit e -Universit€ atsmedizin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ernst</forename><surname>Wellnhofer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Medicine/Cardiology</orgName>
								<address>
									<addrLine>Deutsches Herzzentrum</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heike</forename><surname>Meyborg</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Medicine/Cardiology</orgName>
								<address>
									<addrLine>Deutsches Herzzentrum</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Stawowy</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Medicine/Cardiology</orgName>
								<address>
									<addrLine>Deutsches Herzzentrum</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arne</forename><forename type="middle">€</forename><surname>Ostman</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Cancer Center Karolinska</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Kintscher</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Center for Cardiovascular Research/CCR</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacology</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Kai</forename><surname>Kappert</surname></persName>
							<email>kai.kappert@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Cardiovascular Research/CCR</orgName>
								<orgName type="department" key="dep2">Institute of Laboratory Medicine</orgName>
								<orgName type="department" key="dep3">Clinical Chemistry and Pathobiochemistry</orgName>
								<orgName type="institution">Charit e -Universit€ atsmedizin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Center for Cardiovascular Research/CCR</orgName>
								<orgName type="department" key="dep2">Institute of Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">Clinical Chemistry and Pathobiochemistry</orgName>
								<orgName type="institution" key="instit2">Charit e -Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Hessische Straße 3-4</addrLine>
									<postCode>10115</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">675F17E932DCE7021DFDA43BCC782ADF</idno>
					<idno type="DOI">10.1002/2211-5463.12000</idno>
					<note type="submission">Received 1 September 2015, revised 16 November 2015, accepted 19 November 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>bis(maltolato)oxovanadium(IV)</term>
					<term>insulin resistance</term>
					<term>protein tyrosine phosphatases</term>
					<term>PTP inhibition</term>
					<term>SHP-1/Ptpn6</term>
					<term>sodium stibogluconate</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Insulin resistance plays a crucial role in the development of type 2 diabetes.</s><s>Insulin receptor signalling is antagonized and tightly controlled by protein tyrosine phosphatases (PTPs).</s><s>However, the precise role of the PTP src homology 2 domain-containing phosphatase 1 (SHP-1) in insulin resistance has not been explored.</s><s>Male C57BL/6J mice were fed a high-fat diet (HFD, 60% kcal from fat), to induce insulin resistance, or a low-fat diet (LFD, 10% kcal from fat) for 10 weeks.</s><s>Afterwards, HFD-fed mice were pharmacologically treated with the SHP-1 (Ptpn6) inhibitor sodium stibogluconate and the broad spectrum pan-PTP inhibitor bis(maltolato)oxovanadium(IV) (BMOV).</s><s>Both inhibitors ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance, which was not due to altered PTP gene expression.</s><s>In parallel, phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt was enhanced, and both PTP inhibitors and siRNA-mediated SHP-1 downregulation resulted in an increased glucose uptake in vitro.</s><s>Finally, recombinant SHP-1 was capable of dephosphorylating the ligand-induced tyrosine-phosphorylated insulin receptor.</s></p><p><s>These results indicate a central role of SHP-1 in insulin signalling during obesity, and SHP-1 inhibition as a potential therapeutic approach in metabolic diseases.</s></p><p><s>Receptor tyrosine kinases (RTKs), like the insulin receptor, are tightly controlled by protein tyrosine phosphatases (PTPs), which together regulate the network cellular tyrosine-phosphorylation status <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>Insulin initiates a signalling cascade after ligation of the insulin receptor, leading to phosphorylation of the insulin receptor itself, substrates, and downstream signalling components <ref type="bibr" target="#b4">[5]</ref>, which is antagonized by different PTPs.</s><s>Imbalance of insulin signalling components can lead to impaired glucose utilization and hyperglycaemia, as being evident in diabetes and insulin resistance <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s></p><p><s>Clinically, insulin resistance is characterized by reduced systemic insulin-response.</s><s>Besides other causes, obesity has been found being both associated with and promoting of insulin resistance.</s><s>Strikingly, in Abbreviations BMOV, bis(maltolato)oxovanadium(IV); GTT, glucose tolerance test; HFD, high-fat diet; ITT, insulin tolerance test; LFD, low-fat diet; PTP, protein tyrosine phosphatase(s); SHP-1, src homology 2 domain-containing phosphatase 1.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>insulin resistance upregulation and altered activity of PTPs have been detected <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>.</s></p><p><s>While 38 classical PTPs with sole tyrosine-dephosphorylation activity are encoded in the human genome <ref type="bibr" target="#b10">[11]</ref>, only a limited number of PTPs was shown to target the insulin receptor <ref type="bibr" target="#b11">[12]</ref>.</s><s>PTP1B, DEP-1, LAR and TC-PTP are known to dephosphorylate tyrosine-phosphorylated residues of the insulin receptor <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>, while SHP-2 was shown to function as a positive regulator of insulin action <ref type="bibr" target="#b17">[18]</ref>.</s><s>Further, Src homology region 2 domain-containing phosphatase-1 (SHP-1) impacts on insulin signalling <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s>SHP-1-deficient mice (Ptpn6 meÀv/meÀv , also known as viable motheaten) were characterized by enhanced insulin receptor signalling in skeletal muscle and liver <ref type="bibr" target="#b18">[19]</ref>.</s><s>Moreover, in experimental diet-induced obesity SHP-1 was shown to be upregulated in the metabolically active tissues skeletal muscle, adipose tissue and the liver <ref type="bibr" target="#b7">[8]</ref>.</s></p><p><s>Sodium stibogluconate represents a SHP-1 inhibitor, which has also been used clinically in the treatment of leishmaniosis <ref type="bibr" target="#b20">[21]</ref>.</s><s>Using sodium stibogluconate we tested the hypothesis that SHP-1 inhibition leads to improvement of insulin sensitivity in a mouse model of high-fat diet (HFD) induced insulin resistance.</s><s>These analyses were extended by analyses of the impact of the broad spectrum pan-PTP inhibitor bis(maltolato) oxovanadium(IV) (BMOV).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Increased insulin signalling with sodium stibogluconate</head><p><s>Sodium stibogluconate, an effective SHP-1 inhibitor <ref type="bibr" target="#b21">[22]</ref>, was used in the liver cell line AML12 to assess the inhibitory impact of SHP-1 in insulin signalling in vitro.</s><s>Immunoblotting analyses were performed to assess the site-specific tyrosine phosphorylation of the insulin receptor and phosphorylation of downstream kinases Akt and Erk1/2 (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Insulin receptor phosphorylation at sites Y 1158 and Y 1361 was enhanced after SHP-1 inhibition both under basal conditions and after insulin incubation.</s><s>Particularly, tyrosine phosphorylation at site Y 1158 was enhanced after 15 min, whereas the tyrosine site Y 1361 revealed an increased phosphorylation already after short time (2 min) insulin stimulation.</s><s>Further, the downstream kinase Akt was also activated after sodium stibogluconate treatment, while Erk1/2 was not affected.</s><s>Specifically, Akt phosphorylation at Ser 473 , a commonly used measure for insulin sensitivity <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b22">23]</ref>, was increased after long term insulin stimulation in the presence of sodium stibogluconate, while insulininduced Erk phosphorylation remained unchanged.</s></p><p><s>Together, sodium stibogluconate treatment resulted in a specific SHP-1 inhibition associated with increased phosphorylation of the insulin receptor and Akt at defined times.</s></p><p><s>HFD in C57BL/6J mice induced insulin resistance HFD mice were characterized by a significantly higher weight gain during the first 10 weeks compared to LFD mice (Fig. <ref type="figure" target="#fig_1">2A</ref>).</s><s>Insulin resistance was induced only in mice subjected to an HFD, whereas control mice fed an LFD remained insulin sensitive, assessed by an insulin tolerance test (ITT) (Fig. <ref type="figure" target="#fig_1">2B</ref>).</s><s>Glucose concentration was significantly increased in HFD-fed mice in the early period after insulin stimulation (15 min, 30 min and 60 min), in contrast to LFD mice.</s><s>In addition, glucose tolerance was also reduced in mice under HFD, based on significantly increased blood glucose concentration after 30 min and 60 min in a glucose tolerance test (GTT) (Fig. <ref type="figure" target="#fig_1">2C</ref>).</s><s>Calculation of the area under the curve (AUC) for ITT and GTT confirmed the significantly reduced insulin sensitivity (Fig. <ref type="figure" target="#fig_1">2D</ref>) and significantly impaired glucose tolerance (Fig. <ref type="figure" target="#fig_1">2E</ref>) in HFD mice.</s><s>Thus, HFD feeding resulted in both impaired glucose and insulin tolerance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PTP inhibition with sodium stibogluconate and BMOV improved the metabolic phenotype in HFD-induced insulin-resistant mice</head><p><s>To investigate whether PTP inhibition led to an improved metabolic phenotype after induction of insulin resistance, HFD mice were pharmacologically treated with the specific SHP-1 inhibitor sodium stibogluconate or the broad spectrum pan-PTP inhibitor BMOV for 6 weeks.</s><s>HFD mice exhibited a constant body weight during this period, while mice treated with sodium stibogluconate showed a slight but insignificant decrease compared to HFD mice.</s><s>In contrast, BMOV treatment resulted in a significant reduction of body weight (Fig. <ref type="figure" target="#fig_3">3A</ref>).</s></p><p><s>Further, the metabolic status was assessed by ITT and GTT measurements.</s><s>After insulin injection the glucose concentration decreased in both sodium stibogluconate and BMOV treatment groups, and achieved statistical significance after 30 min compared to HFD mice (Fig. <ref type="figure" target="#fig_3">3B</ref>).</s><s>However, the improved insulin sensitivity in the early period in sodium stibogluconate and BMOV-treated mice did not translate into a significantly decreased AUC, in particular due to slightly higher glucose values at the late phase (Fig. <ref type="figure" target="#fig_3">3C</ref>).</s><s>Furthermore, glucose injection resulted in reduced blood glucose concentration in both sodium stibogluconate and BMOV groups with significantly decreased blood glucose values after 60 min and 90 min compared to HFD mice (Fig. <ref type="figure" target="#fig_3">3D</ref>).</s><s>This was consistent with a significantly reduced AUC in mice treated with sodium stibogluconate (Fig. <ref type="figure" target="#fig_3">3E</ref>).</s><s>However, the change in the AUC in BMOV-treated animals did not reach statistical significance, based on minor differences in glucose levels at the 30 min time point.</s></p><p><s>To confirm the efficacy of the pharmacological treatment with BMOV in insulin-resistant mice, metabolic tissues were used for pan-PTP activity measurements.</s><s>Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice (Fig. <ref type="figure" target="#fig_4">4A-C</ref>).</s></p><p><s>In addition to PTP activity measurements, mRNA levels were analysed to rule out counterregulation of different PTPs caused by inhibition with BMOV and sodium stibogluconate in liver, skeletal muscle and adipose tissue compared to HFD mice.</s><s>As shown in Fig. <ref type="figure" target="#fig_5">5A-C</ref>, no significant differences in gene expression levels were detected for SHP-1, SHP-2, PTP1B, TC-PTP, DEP-1 and LAR in the three analysed animal groups.</s></p><p><s>To summarize, PTP inhibition with sodium stibogluconate and BMOV improved the metabolic phenotype in HFD mice, in particular with regard to glucose utilization.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Glucose uptake is increased in C2C12 cells after PTP inhibition with sodium stibogluconate and BMOV</head><p><s>PTP inhibition led to increased phosphorylation in insulin signalling in vitro accompanied by an improved glucose tolerance after PTP inhibition in vivo.</s><s>Thus, to investigate whether muscle cells were impacting on the improved glucose homeostasis, differentiated C2C12 cells were used for glucose uptake assays.</s><s>Insulin stimulated glucose uptake was examined without PTP inhibition and in sodium stibogluconate and BMOVtreated cells.</s><s>These results showed that PTP inhibition with both pharmacological compounds led to an increased insulin-induced glucose uptake compared to</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body weight [%]</head><p><s>Sodium stibogluconate untreated cells (Fig. <ref type="figure" target="#fig_6">6A-B</ref>).</s><s>To underline the impact of SHP-1, additionally, siRNA-mediated SHP-1 downregulation was applied in C2C12 cells, followed by glucose uptake measurements.</s><s>A significantly increased glucose uptake was observed after siRNA-SHP-1 transfection (Fig. <ref type="figure" target="#fig_6">6C</ref>), consistent with significantly reduced SHP-1 mRNA levels without counterregulatory changes in gene expression of the insulin receptor and other PTPs (Fig. <ref type="figure" target="#fig_6">6D</ref>).</s><s>Hence, PTP inhibition in skeletal muscle cells in vitro likely impacts on insulin signalling, demonstrated by improved glucose utilization.</s><s>This is consistent with the ability of recombinant SHP-1 protein to dephosphorylate the insulin-induced phosphorylated insulin receptor (Fig. <ref type="figure" target="#fig_6">6E</ref>).</s><s>This capability of SHP-1 for insulin receptor dephosphorylation was comparable to recombinant PTP1B.</s><s>As PTP1B has earlier been described to dephosphorylate the insulin receptor at site Y 1162/63 <ref type="bibr" target="#b24">[24]</ref>, we focused on analyses of this site.</s><s>To confirm the tyrosine-dephosphorylation activity, prior incubation with the PTP inhibitor sodium vanadate resulted in inactivation of SHP-1 and PTP1B, leading to the loss of dephosphorylating capacity (Fig. <ref type="figure" target="#fig_6">6E</ref>).</s><s>Taken together, PTP inhibition is strongly associated with increased insulin receptor phosphorylation, and sodium stibogluconate and BMOV treatment leads to significantly increased glucose uptake in skeletal muscle cells.</s></p><formula xml:id="formula_0">HFD BMOV † † † † † † † † † † † † † † † † † † † † † † † † † † † † † † † C<label>0</label></formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>While SHP-1 deficient mice are known to exhibit enhanced insulin signalling <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b18">19]</ref>, a pharmacological approach inhibiting SHP-1 had not been performed previously.</s><s>In this study, sodium stibogluconate, a specific SHP-1 inhibitor, and BMOV, a broad spectrum pan-PTP inhibitor were applied in HFDinduced insulin-resistant mice as a treatment approach.</s><s>Both pharmacological regimens antagonized metabolic changes induced by HFD feeding.</s><s>PTP inhibitortreated mice were characterized by increased insulin sensitivity and glucose tolerance in vivo, which was not due to altered PTP gene expression, including SHP-1.</s><s>Moreover, application of both PTP inhibitors showed an increased glucose uptake in skeletal muscle cells.</s><s>This was consistent with enhanced phosphorylation of key intermediates in insulin signalling after SHP-1 inhibition and glucose uptake after siRNA-mediated SHP-1 downregulation in vitro.</s></p><p><s>Deletion of serine/threonine phosphatases <ref type="bibr" target="#b25">[25]</ref> and in particular protein tyrosine phosphatases <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b26">26]</ref> has earlier been shown to result in an improved metabolic phenotype in insulin resistance and diabetes.</s><s>Moreover, elevated expression and activity of PTPs was detected in metabolic tissues in HFD-induced insulin-resistant mice earlier <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b27">27]</ref>, including SHP-1 <ref type="bibr" target="#b7">[8]</ref>.</s><s>Based on these data, SHP-1 represents a potential therapeutic target for pharmacological intervention with sodium stibogluconate, a potent SHP-1 inhibitor <ref type="bibr" target="#b21">[22]</ref>.</s><s>Therefore, AML12 liver cells were chosen for analysing the phosphorylation level of intermediates of the insulin signalling pathway.</s><s>After SHP-1 inhibition, increased phosphorylation of the insulin receptor and the downstream kinase Akt, suggest that SHP-1 may be a suitable drug target.</s><s>This is consistent with the data recently received in mice with hepatocyte-specific Ptpn6 deletion, resulting in lower fasting glucose and improved hepatic insulin sensitivity <ref type="bibr" target="#b7">[8]</ref>.</s><s>To analyse the impact of a pharmacological PTP inhibition in vivo a commonly used model of insulin resistance induced by HFD feeding was applied in mice <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29]</ref>.</s><s>These animals were characterized by significant weight gain along with impaired insulin sensitivity and reduced glucose tolerance.</s><s>Based on the in vitro data with enhanced insulin signalling in liver cells after SHP-1 inhibition, insulin-resistant mice were pharmacologically treated with sodium stibogluconate, also known to distribute in vivo <ref type="bibr" target="#b30">[30]</ref>.</s><s>Furthermore, the impact of the broad spectrum pan-PTP inhibitor BMOV, previously only analysed in diabetic rats <ref type="bibr" target="#b31">[31]</ref>, was explored.</s></p><p><s>BMOV is characterized by a nonselective inhibition of different PTPs <ref type="bibr" target="#b32">[32]</ref>, including PTP1B <ref type="bibr" target="#b34">[33]</ref>.</s><s>Metabolic phenotypingbody weight, ITT, GTTrevealed in both pharmacological groups a beneficially altered metabolic status in HFD-induced insulin resistance.</s><s>All analysed metabolic parameters were improved after PTP inhibition, evidenced by reduction in body weight, improved insulin sensitivity and enhanced The metabolic phenotype could not be explained by differences in epididymal fat mass or physical activity (data not shown).</s><s>In contrast, the improved glucose tolerance, measured by the GTT, was substantiated by increased glucose uptake obtained in mouse skeletal muscle cells after PTP inhibition and transfection of siRNA against SHP-1 in vitro.</s><s>Furthermore, data from rat L6 myocytes after adenoviral mediated expression of a catalytically inert DNSHP-1 mutant <ref type="bibr" target="#b19">[20]</ref> are consistent with our data obtained in mouse C2C12 cells.</s><s>Recombinant SHP-1, as the known component in insulin signalling PTP1B, was capable in insulin receptor dephosphorylation in vitro, which was antagonized by prior PTP inhibition.</s><s>These data further support SHP-1 as novel target for antidiabetic drugs.</s><s>BMOV is rapidly absorbed and distributed in various tissues <ref type="bibr" target="#b35">[34]</ref>.</s><s>It has previously been reported to augment VEGF receptor and insulin receptor signalling and to modulate specific cell functions such as cell proliferation and insulin sensitivity in rats <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b36">35]</ref>.</s><s>BMOV is an organic vanadate derivate with potent and broad spectrum PTP inhibition properties.</s><s>Our observation that BMOV treatment resulted in a significant reduction in PTP activity in the metabolic tissues liver, skeletal muscle and adipose tissue validated adequate drug distribution in vivo.</s><s>The precise underlying mechanism for BMOV-induced weight loss remains to be determined.</s><s>It might, at least partly, be due to altered insulin signalling based on PTP1B-inhibitory action, since BMOV also inhibits PTP1B.</s><s>In fact, PTP1B knockout has earlier been shown to protect against weight gain <ref type="bibr" target="#b12">[13]</ref>.</s><s>Finally, our data are in accordance with weight loss in BMOV-treated rats <ref type="bibr" target="#b37">[36]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver</head><p><s>Sodium stibogluconate is primarily applied to treat leishmaniose infections <ref type="bibr" target="#b38">[37]</ref> but it is also been used in a clinical phase I trial as an anticancer drug to target SHP-1 <ref type="bibr" target="#b39">[38]</ref>.</s><s>Pharmadynamic studies with sodium stibogluconate earlier revealed drug efficacy in the liver <ref type="bibr" target="#b30">[30]</ref>.</s><s>The inhibitory effect with recombinant SHP-1 has been shown earlier <ref type="bibr" target="#b21">[22]</ref>.</s><s>Furthermore, both pharmacological approaches did not influence the expression of the PTPs SHP-1, SHP-2, PTP1B, TC-PTP, DEP-1 and LAR, which all have been implicated as regulators in insulin signalling or insulin resistance earlier.</s><s>Therefore, these data underline that the observed effects during 6 weeks BMOV and sodium stibogluconate treatment were due to inhibition of PTP activity and not due to expression changes.</s><s>However, after in vivo application of sodium stibogluconate, given at a dose that was shown to exhibit significant antileishmanial property in rodents <ref type="bibr" target="#b40">[39]</ref>, we were not able to detect a strong SHP-1 inhibition in isolated metabolic tissues (not shown), which is, however, consistent with previous observations <ref type="bibr" target="#b41">[40]</ref>.</s><s>Therefore, we further performed sodium stibogluconate treatment of cultured AML12 cells, followed by immunoprecipitation of SHP-1 and activity measurements.</s><s>In these experiments we could detect a small reduction (~13%, P = 0.065) in SHP-1 activity (not shown).</s><s>This suggests thatcontrasting the strong in vivo metabolic effects and impact on recombinant SHP-1 <ref type="bibr" target="#b21">[22]</ref> the lack of a significant detectable SHP-1 inhibition in tissues and cultured cells is presumably based on either transient inhibitory efficiency of sodium stibogluconate in vivo or on processing specifics of the animal tissues in vitro.</s><s>Furthermore, our data showing in vivo efficacy are underlined by demonstration of sodium stibogluconate clearly reducing leishmanial skin lesions in a clinical study in patients applying also the same drug concentration (20 mgÁkg À1 Áday À1 ) as in our experimental protocol <ref type="bibr" target="#b42">[41]</ref>.</s></p><p><s>Inhibiting the ubiquitously expressed SHP-1 in wildtype mice clearly demonstrated the beneficial metabolic effects in our study, without causing any detectable side effects.</s><s>However, the phenotype of two different conditional SHP-1 knockout models should be acknowledged.</s><s>Motheaten and viable motheaten mice, expressing no active or low levels of catalytic inactive SHP-1, respectively, are characterized by severe abnormalities along with a reduced life span <ref type="bibr" target="#b43">[42]</ref>.</s><s>Nevertheless, viable motheaten mice are also characterized by improved insulin sensitivity and glucose tolerance due to enhanced insulin signalling in liver and skeletal muscle.</s></p><p><s>Taken together, this study showed the therapeutic potential of sodium stibogluconate in metabolic diseases.</s><s>Inhibiting SHP-1 by sodium stibogluconate was followed by enhanced insulin signalling, leading to a phenotype in mice with increased insulin sensitivity and glucose tolerance.</s><s>These data support a novel pharmacological approach to treat insulin resistance by sodium stibogluconate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals and treatment</head><p><s>C57BL/6J mice were purchased from Janvier (Le Genest-Saint-Isle, France).</s><s>Mice aged 4-6 weeks were fed ad libitum a low-fat diet (LFD) (n = 10) (10% kcal from fat; Altromin, Lage, Germany) or a high-fat diet (HFD) (n = 45) (60% kcal from fat; Altromin) for 10 weeks.</s><s>Afterwards, intraperitoneal application of sodium stibogluconate (Calbiochem, Schwalbach, Germany) [20 mg/kg body weight] (n = 15) was carried out daily, or twice weekly with BMOV (Organica, Wolfen, Germany) [0.75-3.0</s><s>mmol] in an escalating application scheme (n = 15), or daily of vehicle in 0.9% carboxymethylcellulose (n = 15) in HFD-fed mice for additional 6 weeks as a treatment approach.</s><s>After metabolic phenotyping mice were sacrificed under isoflurane anaesthesia.</s><s>All animal procedures were in accordance with institutional guidelines and were approved by the Landesamt f€ ur Gesundheit und Soziales (LAGeSo, Berlin, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Metabolic phenotyping (body weight, ITT, GTT)</head><p><s>Twice weekly body weight was recorded throughout the study period.</s><s>In fasted mice an intraperitoneal insulin tolerance test (ITT) was performed by using insulin (Insuman Ò Rapid, Sanofi Aventis, Berlin, Germany) in a dose of 0.5 UÁkg À1 and an intraperitoneal glucose tolerance test (GTT) with 1 gÁkg À1 glucose (Glucosteril, Fresenius, Bad Homburg, Germany).</s><s>Glucose concentration of tail vein blood was measured at indicated time points by using a glucometer (Precision Xceed, Abbott, Wiesbaden, Germany).</s></p><p><s>Cell culture, PTP inhibition glucose uptake and siRNA transfection C2C12 myoblasts and AML12 liver cells were purchased from American Type Culture Collection (ATCC Ò , Wesel, Germany) and maintained in DMEM (Dulbecco's Modified Eagle Medium) or DMEM/F12, respectively, containing 10% FBS and 1% penicillin/streptomycin at 37 °C in an atmosphere of 95% air and 5% CO 2 .</s><s>Insulin stimulation in AML-12 was performed in cells fasted over night by adding insulin [3 nM] for indicated time periods.</s><s>Differentiation of C2C12 cells to myotubes was carried out for 6 days followed by glucose uptake experiments as described earlier <ref type="bibr" target="#b13">[14]</ref>.</s><s>PTP inhibition was done by adding sodium stibogluconate [11 lM] and BMOV [50 lM]both dissolved in waterfor 1 h before each experiment was performed.</s><s>Transfection of C2C12 cells was carried out using 10 nM siRNA against SHP-1 (Thermo Fisher Scientific, Bonn, Germany), and Lipofectamine Ò RNAiMAX (Invitrogen, Karlsruhe, Germany) for 72 h according to the manufacturer's (Invitrogen) recommendations.</s><s>Cells transfected with nontargeting siRNA served as control.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein tyrosine phosphatase activity</head><p><s>Pan-PTP activity in metabolic tissues (liver, skeletal muscle, adipose tissue) was measured by using a radioactive labelled peptide as described previously <ref type="bibr" target="#b14">[15]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitative real-time PCR (qPCR)</head><p><s>RNA was isolated with RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instruction for purification from C2C12 cells and tissue (liver, skeletal muscle, adipose tissue), and cDNA synthesis was done with SuperScript Ò II (Invitrogen).</s><s>Quantitative real-time PCRs were performed with SybrGreen (Applied Biosystems, Darmstadt, Germany) in duplicate per condition.</s><s>The expression of analysed genes was normalized to the average expression of the housekeeping gene Rn18s.</s></p><p><s>The following primer sequences (final concentrations 100 nM) were used (forward and reverse respectively):</s></p><p><s>Insr 5 0 -CAATGGGACCACTGTATGCATCT-3 0 , 5 0 -ACT CGTCCGGCACGTACAC-3 0 ; Ptpn1 5 0 -CGGGAGGTCAGGGACCTT-3 0 , 5 0 -GGGTCT TTCCTCTTGTCCATCA-3 0 ; Ptpn2 5 0 -GCTACGACGGCTCAGAAGGT-3 0 , 5 0 -TGTC TGTCAATCTTGGCCTTTTT-5 0 ; Ptprf 5 0 -ACCCGATGGCTGAGTACAAC-3 0 , 5 0 -GCCT TCACCTGTTTTGGGTA-5 0 ; Ptpn6 5 0 -CGTACCCTCCCGCTGTGA-3 0 , 5 0 -TTTTCGT ACACCTCCTCCTTGTG-3 0 ; Ptpn11 5 0 -CCTCAACACAACTCGTATCAATGC-3 0 , 5 0 -TGTTGCTGGAGCGTCTCAAA-3 0 ; Ptprj 5 0 -GCAGTGTTTGGATGTATCTTT-3 0 , 5 0 -CTTCA TTATTCTTGGCATCTGT-3 0 ; Rn18s 5 0 -GACTCTTTCGAGGCCCTGTA-3 0 , 5 0 -CACCA GACTTGCCCTCCAAT-3 0 .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoblotting and dephosphorylation assay</head><p><s>Preparation of protein lysates and immunoblotting was done by standard protocols with primary antibodies (antiphospho insulin receptor Y 1158 , anti-phospho insulin receptor Y 1361 , anti-phospho insulin receptor Y 1162/63 (Abcam, Cambridge, UK), anti-phospho Akt (Ser 473 ), anti-pan Akt, anti-insulin receptor (4B8), anti-phospho Erk, anti-pan Erk (Cell Signaling/New England Biolabs, Frankfurt, Germany) and anti-GAPDH (Millipore, Schwalbach, Germany).</s><s>The recombinant proteins PTP1B and SHP-1 (Abcam) were used for the dephosphorylation assay with phosphorylated insulin receptor as described <ref type="bibr" target="#b14">[15]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Data are expressed as mean AE standard error of the mean (SEM).</s><s>Statistically significant (P &lt; 0.05) differences between the groups were determined by one-way ANOVA analysis with post hoc correction (Bonferroni) or t-test and nonparametric tests (Mann-Whitney U) as appropriate (SPSS V 21, IBM, Ehningen, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>experiments. PS, A €</head><p><s>O and UK critically revised the manuscript and contributed to interpretation and discussion.</s><s>All authors approved the final version of the manuscript.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig.1.</s><s>SHP-1 inhibition with sodium stibogluconate increased insulin receptor phosphorylation.</s><s>AML12 cells were treated with or without sodium stibogluconate followed by insulin stimulation [3 nM] for immunoblotting.</s><s>Site-specific phosphorylation levels of the insulin receptor and insulin signalling downstream kinases Akt and Erk were analysed.</s><s>Shown is one representative immunoblot of n = 3 independent experiments.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. HFD feeding induced insulin resistance in C57BL/6J mice.</s><s>Mice were fed a LFD and HFD over a period of 10 weeks.</s><s>(A) The body weight was determined twice weekly.</s><s>(B-E) Metabolic phenotyping included an ITT (B) and GTT (C) in fasted mice and the AUC was calculated for ITT (D) and GTT (E).</s><s>*P &lt; 0.05; **P &lt; 0.01; ***P &lt; 0.001 LFD vs. HFD; LFD: n = 10; HFD: n = 15.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Pharmacological PTP inhibition increased insulin sensitivity and glucose tolerance in HFD mice.</s><s>(A) Body weight was measured twice weekly during the pharmacological treatment.</s><s>(B) An ITT was performed after PTP inhibition in fasted mice.</s><s>(C) The AUC was calculated for ITT.</s><s>(D) A GTT was carried out in all treatment groups with fasted mice.</s><s>(E) The AUC was calculated for GTT (E).</s><s>‡ P &lt; 0.05; ‡ ‡ P &lt; 0.01 sodium stibogluconate vs. HFD; † P &lt; 0.05, † † P &lt; 0.01, † † † P &lt; 0.001 BMOV vs. HFD; HFD, sodium stibogluconate, BMOV: each group n = 15.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 4 .</head><label>4</label><figDesc><div><p><s>Fig.<ref type="bibr" target="#b3">4</ref>.</s><s>BMOV treatment reduced pan-PTP activity in metabolic tissues.</s><s>Measurements of PTP activity were performed in liver (A), skeletal muscle (B) and adipose tissue (C) of BMOV treated mice compared to HFD mice.</s><s>Crude protein lysates were used for activity measurement with a radioactive labelled peptide.</s><s>† † P &lt; 0.01 HFD vs. BMOV; † † † P &lt; 0.001 HFD vs. BMOV; n = 10-11 for each group.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 5 .</head><label>5</label><figDesc><div><p><s>Fig. 5. PTPs are not differentially expressed after PTP inhibition in metabolic tissues.</s><s>Measurements of PTP expression on mRNA level were performed in liver (A), skeletal muscle (B) and adipose tissue (C) of BMOV and sodium stibogluconate treated mice compared to HFD mice.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 6 .</head><label>6</label><figDesc><div><p><s>Fig. 6.</s><s>PTP inhibition resulted in enhanced glucose uptake accompanied by increased insulin receptor phosphorylation.</s><s>(A-B) Differentiated C2C12 cells were treated with sodium stibogluconate (A), BMOV (B) and transfected with SHP-1 siRNA (C) followed by measurement of insulin-induced glucose uptake.</s><s>Expression of mRNA was analysed to confirm efficient SHP-1 downregulation and to rule out compensatory regulation of the insulin receptor and other PTPs (D).</s><s>(*P &lt; 0.05; **P &lt; 0.01).</s><s>(E) Dephosphorylation assay was performed with precipitated insulin receptor, which served as substrate for recombinant SHP-1 and PTP1B.</s><s>To visualize the dephosphorylation of the insulin receptor immunoblotting was done with depicted antibodies.</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">FEBS Open Bio 6 (2016) 179-189 ª 2015 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd SHP-1 inhibition increases insulin sensitivity J. Kr€ uger et al.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="186">FEBS Open Bio 6 (2016) 179-189 ª 2015 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd SHP-1 inhibition increases insulin sensitivity J. Kr€ uger et al.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">FEBS Open Bio 6 (2016) 179-189 ª 2015 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="188">FEBS Open Bio 6 (2016) 179-189 ª 2015 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd SHP-1 inhibition increases insulin sensitivity J. Kr€ uger et al.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We acknowledge support by the Deutsche Diabetes Gesellschaft (DDG), the Deutsche Forschungsgemeinschaft (DFG) (KA1820/4-1), the Charit e -Univer-sit€ atsmedizin Berlin (personal funding) and the Marga und Walter Boll-Stiftung (210-04-10) to KK. UK was supported by the Deutsche Forschungsgemeinschaft (FG1054 and KFO218) and A € O by a project research grant from Swedish Research Council.</s><s>This work was further supported by a grant of the Charit e-Nachwuchskommission and the Deutsche Akademische Austauschdienst (DAAD, D/12/40985) to JK.</s><s>We are thankful to Frank D. B€ ohmer for fruitful discussions.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head><p><s>JK and KK designed and performed the study, performed experiments, analysed data, wrote, reviewed and edited the manuscript.</s><s>EW analysed data and assisted with drafting the manuscript; HM performed</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Protein tyrosine phosphatases-from housekeeping enzymes to master regulators of signal transduction</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Tonks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="346" to="378" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance</title>
		<author>
			<persName><forename type="first">E</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Endocr Metab Disord</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="79" to="97" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Expression of protein-tyrosine phosphatases in the major insulin target tissues</title>
		<author>
			<persName><forename type="first">K</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Kono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vestergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Theofilopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Moller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">415</biblScope>
			<biblScope unit="page" from="243" to="248" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Special issue: Protein phosphatases: from molecules to networks: introduction</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Tonks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page">323</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">How insulin engages its primary binding site on the insulin receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Menting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Margetts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kletvikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jiracek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">493</biblScope>
			<biblScope unit="page" from="241" to="245" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Defronzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1270" to="1287" />
			<date type="published" when="2009">2010. 2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Protein tyrosine phosphatases in health and disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Hendriks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Elson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harroch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pulido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stoker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Den Hertog</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="708" to="730" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance</title>
		<author>
			<persName><forename type="first">E</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Charbonneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Rolland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bellmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Siminovitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Neel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Beauchemin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1949" to="1958" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice</title>
		<author>
			<persName><forename type="first">I</forename><surname>Garcia-Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Solis-Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gomez-Izquierdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Munoz-Yague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Valverde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Solis-Herruzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="19564" to="19573" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Goldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="2474" to="2480" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Protein tyrosine phosphatases: from genes, to function, to disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Tonks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="833" to="846" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Protein tyrosine phosphatases: the quest for negative regulators of insulin action</title>
		<author>
			<persName><forename type="first">E</forename><surname>Asante-Appiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kennedy</forename><surname>Bp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="page" from="E663" to="E670" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene</title>
		<author>
			<persName><forename type="first">M</forename><surname>Elchebly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Payette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Michaliszyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cromlish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Loy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Normandin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Himms-Hagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="1544" to="1548" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kruger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brachs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trappiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kintscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Meyborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wellnhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thone-Reineke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stawowy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ostman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Birkenfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Metab</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="325" to="336" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kruger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trappiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dagnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stawowy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Meyborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bohm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhanot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ostman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kintscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kappert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Commun Signal</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">49</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Zabolotny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Peroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Boss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Klaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kamatkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Shulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Kahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="5187" to="5192" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tiganis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="445" to="458" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Milarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Saltiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Pessin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="664" to="668" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dombrowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perreault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fournes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Faure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Beauchemin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Shulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="549" to="556" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Inhibition of the protein tyrosine phosphatase SHP-1 increases glucose uptake in skeletal muscle cells by augmenting insulin receptor signaling and GLUT4 expression</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bellmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Larochelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nalbantoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="4581" to="4588" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Randomized, double-blind, controlled, comparative study on intralesional 10% and 15% hypertonic saline versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Ranawaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Weerakoon</forename><surname>Hs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>De Silva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="555" to="563" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Pathak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Yi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="3391" to="3397" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Veras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">N</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Nachbar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>De Jesus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Camporez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Carpinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Goedecke</forename><surname>Jh</surname></persName>
		</author>
		<author>
			<persName><surname>De</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">DHEA supplementation in ovariectomized rats reduces impaired glucosestimulated insulin secretion induced by a high-fat diet</title>
		<author>
			<persName><forename type="first">Oliveira</forename><surname>Carvalho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS open bio</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="141" to="146" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP</title>
		<author>
			<persName><forename type="first">S</forename><surname>Galic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Kahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Haj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Neel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Tonks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tiganis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="819" to="829" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain</title>
		<author>
			<persName><forename type="first">N</forename><surname>Grankvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Honkanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sjoholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ortsater</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">587</biblScope>
			<biblScope unit="page" from="3869" to="3874" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Klaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Boss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Peroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Martino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Zabolotny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Moghal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lubkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Sharpe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="5479" to="5489" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/ nuclear factor kappa B axis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Panzhinskiy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nair</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e77228</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Diet-induced type II diabetes in C57BL/6J mice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Surwit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cochrane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mccubbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Feinglos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1163" to="1167" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">High-fat diet-induced changes in liver thioredoxin and thioredoxin reductase as a novel feature of insulin resistance</title>
		<author>
			<persName><forename type="first">H</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ye</forename></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS open bio</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="928" to="935" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nieto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alvar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Mullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">San</forename><surname>Andres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename></persName>
		</author>
		<author>
			<persName><forename type="first">San</forename><surname>Andres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Baillie</forename><forename type="middle">Aj</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="2781" to="2787" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato) oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Gerwe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kasibhatla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Biol Med (Maywood)</title>
		<imprint>
			<biblScope unit="volume">230</biblScope>
			<biblScope unit="page" from="207" to="216" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pokross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rastogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Greis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Eby-Wilkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Evdokimov</surname></persName>
		</author>
		<title level="m">Mechanism of insulin sensitization by BMOV</title>
				<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>bis maltolato oxo vanadium</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">unliganded vanadium (VO4) as the active component</title>
	</analytic>
	<monogr>
		<title level="j">J Inorg Biochem</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="321" to="330" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Bis (maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mohammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><forename type="middle">J</forename><surname>Mcneill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biochem</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="page" from="125" to="128" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharm Pharmacol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="99" to="105" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Eby-Wilkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Towne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Dufresne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Heart Circ Physiol</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="H268" to="H276" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Effect of vanadium on insulin sensitivity and appetite</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuen</forename><surname>Vg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Mcneill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="667" to="673" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Use of antimony in the treatment of leishmaniasis: current status and future directions</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Haldar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Biol Int</title>
		<imprint>
			<biblScope unit="page">571242</biblScope>
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Elson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitsuhashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hollovary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Budd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Spiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Triozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Borden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1155" to="1164" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Therapeutic use of quercetin in the control of infection and anemia associated with visceral leishmaniasis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mandal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Saha</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mukhopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Biswas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1257" to="1264" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Inhibition of protein tyrosine phosphatases enhances cerebral collateral growth in rats</title>
		<author>
			<persName><forename type="first">I</forename><surname>Buschmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hackbusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gatzke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dulsner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trappiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dagnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ostman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hooft Van Huijsduijnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kappert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Med (Berl)</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="983" to="994" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">A randomized, double-blind study of the efficacy of a 10-or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Oster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jackson</forename><forename type="middle">J</forename><surname>Aronson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="261" to="267" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kozlowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mlinaric-Rascan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Siminovitch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="2157" to="2163" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
